"Based on the positive data to date and the fact that the study objectives of safety and detectability are being met, the Company is now planning for a Phase II study, most likely in the US. The Phase I study will remain open for enrolment to accumulate additional data that will contribute to our evaluation of the diagnostic performance and inform future study design considerations."
IBX Price at posting:
2.2¢ Sentiment: Buy Disclosure: Held
